Posted by Michael Wonder on 22 Nov 2016
U.S. FDA grants fast track designation for the development of Oragenics’ AG013 for oral mucositis
21 November 2016 - Oragenics today announced that the U.S. FDA granted fast track designation to AG013, the Company’s lead therapeutic candidate for the treatment of oral mucositis
Oragenics expects to file an investigational new drug update and initiate a Phase 2 study with AG013 in the United States and Europe in early 2017.
